|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
23rd November, 2004
GlaxoSmithKline reviews novel therapeutics for CNS disorders and confirms strong pipeline momentum
GlaxoSmithKline reviews novel therapeutics for CNS disorders and confirms strong pipeline momentum
Issued – Tuesday 23 November 2004, London
Today GlaxoSmithKline [NYSE: GSK] gave investors and financial analysts an update on its compounds in development to treat Central Nervous System disorders, a therapy area that represents approximately 20% of the company’s total R&D pipeline ...
|
22nd November, 2004
FDA approves Vesicare ® (solifenacin succinate) for the treatment of overactive bladder
FDA approves Vesicare® (solifenacin succinate) for the treatment of overactive bladder
—New Once-Daily Product Reduces Incontinence Episodes in Patients with OAB—
Paramus, NJ and Research Triangle Park, NC - November 22, 2004 - Vesicare® (solifenacin succinate) has been approved by the U.S ...
|
18th November, 2004
GlaxoSmithKline stands firmly behind Serevent
GlaxoSmithKline stands firmly behind Serevent
Philadelphia, November 18, 2004 GlaxoSmithKline [NYSE: GSK] issued the following statement in response to comments made today by David Graham, Associate Science Director of the Office of Drug Safety at the Food and Drug Administration (FDA), with regard to Serevent (salmeterol), a widely used and highly effective treatment for asthma and chronic obstructive pulmonary disease (COPD) marketed by GSK:
GlaxoSmithKline stands firmly behind Serevent, which is safe and effective when used appropriately and in accordance with labeling and treatment guidelines ...
|
18th November, 2004
Updated Federal Guidelines recommend Retrovir + Epivir as part of first-line therapy in ART regimens
Updated Federal Guidelines recommend Retrovir + Epivir as part of first-line therapy in ART regimens
Research Triangle Park, N.C. - November 18, 2004 – Revised federal guidelines recommend RETROVIR® (zidovudine, ZDV) and EPIVIR® (lamivudine, 3TC) as one of the preferred dual nucleoside reverse transcriptase inhibitor (NRTI) “backbones” used as part of initial HIV combination therapy ...
|
15th November, 2004
GlaxoSmithKline announces drug tracking effort to support FDA battle against counterfeit drugs
GlaxoSmithKline announces drug tracking effort to support FDA battle against counterfeit drugs
PHILADELPHIA, NOVEMBER 15, 2004 - GlaxoSmithKline [NYSE: GSK] today announced that it will begin using radio frequency identification (RFID) tags in the next 12 to 18 months on at least one product deemed susceptible to counterfeiting in order to more effectively monitor its progress from the company to the patient ...
|
10th November, 2004
GlaxoSmithKline sponsors online resource about prescription drugs
GlaxoSmithKline sponsors online resource about prescription drugs
Philadelphia, PA — November 10, 2004 — Looking for answers to your questions about why prescription medicines cost what they do in the US? Want to know how much the pharmaceutical industry spends on R&D versus direct-to-consumer advertising? A new Internet resource - The Center For Plain Talk About Medicines in America - answers these and a host of other questions about the cost, quality and value of prescription drugs in the United States ...
|
9th November, 2004
Study shows impact of Coreg ® (carvedilol) on cardiovascular risk factors in patients with diabetes and hypertension
Study shows impact of Coreg® (carvedilol) on cardiovascular risk factors in patients with diabetes and hypertension
EMBARGOED UNTIL 7:30 a.m. CST, Tuesday, Nov. 9, 2004
Results Unveiled in the Journal of the American Medical Association and at the 2004 American Heart Association Scientific Sessions
Philadelphia, PA, November 9, 2004 – A newer beta-blocker Coreg® (carvedilol) may provide advantages in patients with diabetes and hypertension, according to study results released today by GlaxoSmithKline (NYSE:GSK) ...
|
1st November, 2004
Lapatinib shows anti-tumour activity in Herceptin - resistant breast cancer patients
Lapatinib shows anti-tumour activity in Herceptin - resistant breast cancer patients
Not for distribution in the US
Issued — Monday 1st November 2004, London, UK & Philadelphia, US
SIX MONTH ANALYSIS OF ONGOING PHASE II TRIAL PRESENTED AT EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO ABSTRACTS #103)
GlaxoSmithKline (NYSE: GSK; LSE) today announced the results from a planned interim analysis of an ongoing Phase II clinical study of once-daily oral Lapatinib (GW572016) in women with heavily pretreated advanced metastatic breast cancer whose disease had previously progressed while on trastuzumab (Herceptin*) containing regimens ...
|
1st November, 2004
Safety and immunogenicity results available for new Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Booster Vaccine (Tdap) candidate for adolescents
Safety and immunogenicity results available for new Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Booster Vaccine (Tdap) candidate for adolescents
Data Presented for First Time at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
WASHINGTON, D.C., November 1, 2004 – GlaxoSmithKline (NYSE:GSK) today reported results from a pivotal clinical study of its booster vaccine candidate Boostrix™ [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap)] ...
|
31st October, 2004
New data supports development of investigational HIV therapy
New data supports development of investigational HIV therapy
Issued — Sunday 31st October 2004, London, UK and Philadelphia, PA
Positive Data for CCR5 Antagonist Presented at 44th Annual ICAAC
Today GlaxoSmithKline (GSK) presented positive results from a Phase 2 study evaluating the short-term safety, tolerability and efficacy of its investigational HIV compound 873140, a cellular chemokine receptor (CCR5) antagonist1 ...
|
|
|
|
« Previous 10 Next 10 » |
|
|
|
|
